Project Details
Description
To develop improved therapeutic approaches whereby T-cell
depleted, HLA haplotype disparate marrow transplants can be
used to consistently achieve engraftment and full recovery of
immune function with graft vs. host disease in patients with: a) variants of SCID exhibiting graft resistance;
b) Other diseases associated with a lethal combined
immunodeficiency, and
c) Wiskott-Aldrich syndrome, who lack an HLA-identical donor
depleted, HLA haplotype disparate marrow transplants can be
used to consistently achieve engraftment and full recovery of
immune function with graft vs. host disease in patients with: a) variants of SCID exhibiting graft resistance;
b) Other diseases associated with a lethal combined
immunodeficiency, and
c) Wiskott-Aldrich syndrome, who lack an HLA-identical donor
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/82 → 6/30/91 |
Funding
- National Institutes of Health